Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference


Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief R&D Officer, will participate in a fireside discussion at the virtual Cantor Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. Eastern Time. Dr. McGraw and Dr. Hollander will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com. A replay of the fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye disease, wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.


These press releases may also interest you

at 00:13
5G is leading the trend of 2021. According to "The 5G Economy" published by IHS Market, the global 5G industry investment will reach US$4 trillion in 2035, and another US$12 trillion will be invested in related applications driven by 5G. Mr....

at 00:00
Crypto Llamas NFT, the rising star of the NFT world, has recently launched the NFT's For Newbies Facebook group. NFT's For Newbies is the place where NFT beginners can learn the ins and outs of NFT's. This is the place where NFT beginners can learn...

15 oct 2021
GetSwift Technologies Limited ("GetSwift" or the "Corporation"; NEO: "GSW"), a leading provider of last mile SaaS logistics technology, is pleased to announce that it has filed its audited annual financial statements for its year ended June 30, 2021...

15 oct 2021
Extreme Vehicle Battery Technologies Corp. (the "Company" or "EV Battery Tech") with its subsidiary IoniX Pro Battery Technologies Inc ("IoniX Pro") are delighted to announce the results of the social media driven sweepstakes (the "Contest")....

15 oct 2021
Helix BioPharma Corp. ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today that it anticipates the filing of its annual financial...

15 oct 2021
Global advertising and marketing agency Channel Bakers announced it has partnered with Skai, a leading commerce intelligence platform, to expand the agency's suite of eCommerce solutions. Agency CEO and Founder Joshua Kreitzer said the Skai...



News published on 27 september 2021 at 07:35 and distributed by: